105 related articles for article (PubMed ID: 1725104)
1. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of serum acute-phase reactants in patients with ovarian tumors.
Warwas M; Dobryszycka W; Gerber J; Pietkiewicz A
Neoplasma; 1981; 28(4):485-90. PubMed ID: 7290269
[TBL] [Abstract][Full Text] [Related]
3. Serum haptoglobin, CA 125 and interleukin 6 levels in malignant and non-malignant tumors of the ovary.
Dobryszycka W; Katnik-Prastowska I; Gerber J; Lemańska K; Utko K; Rozdolski K
Arch Immunol Ther Exp (Warsz); 1999; 47(4):229-36. PubMed ID: 10483871
[TBL] [Abstract][Full Text] [Related]
4. [Sequential determination of circulating immune complexes in ovarian tumors].
Beaufort F; Auner H; Lahousen M
Wien Med Wochenschr; 1986 Jul; 136(13):317-22. PubMed ID: 3765649
[TBL] [Abstract][Full Text] [Related]
5. Lipid associated sialic acid in plasma in patients with advanced carcinoma of the ovaries.
Vardi JR; Tadros GH; Malhotra C; Charney T; Shebes M; Foemmel R
Surg Gynecol Obstet; 1989 Apr; 168(4):296-301. PubMed ID: 2928903
[TBL] [Abstract][Full Text] [Related]
6. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
Yue K; Bian M; Zhu D; Liu W; Siu S
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
[TBL] [Abstract][Full Text] [Related]
7. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
Vardi JR; Tadros GH; Foemmel R; Shebes M
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
[TBL] [Abstract][Full Text] [Related]
8. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
9. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
[TBL] [Abstract][Full Text] [Related]
10. A case control study of glycoprotein status in ovarian carcinoma.
Aranganathan S; Senthil K; Nalini N
Clin Biochem; 2005 Jun; 38(6):535-9. PubMed ID: 15885233
[TBL] [Abstract][Full Text] [Related]
11. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of serum ferritin and acute phase reactant proteins levels in patients with cervical cancer].
Xie JF
Zhonghua Fu Chan Ke Za Zhi; 1991 Mar; 26(2):92-4, 124. PubMed ID: 1713541
[TBL] [Abstract][Full Text] [Related]
13. A sequential study of humoral factors in ovarian neoplasms.
Gupta SC; Agarwal J; Singh PA; Mehdiratta NK; Keswani NK
Indian J Pathol Microbiol; 1994 Jul; 37(3):319-26. PubMed ID: 7814065
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
15. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
16. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
[TBL] [Abstract][Full Text] [Related]
17. [Tumor markers in the monitoring of ovarian cancer].
Xu SX
Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
[TBL] [Abstract][Full Text] [Related]
18. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
Tang BJ; Li L; Xu J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
20. Shed membrane fragment-associated markers for endometrial and ovarian cancers.
Taylor DD; Lyons KS; Gerçel-Taylor C
Gynecol Oncol; 2002 Mar; 84(3):443-8. PubMed ID: 11855885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
